Get the latest analysis on Heron Therapeutics (HRTX): current challenges, future outlook, and key growth factors. Click here ...

Evaluate how FTAs, HS codes, and duty-drawback mechanisms can optimize import costs, compliance, and liquidity for foreign ...

CEO Treace stated, "we are not growing our line the way we anticipated for the year," while also noting case volume growth in ...

Discover AirSculpt Technologies' Q3 2025 earnings, strategic pivots for GLP-1 users, cost controls, and North America focus.

Operator: Hello, and thank you for standing by. My name is Mark, and I will be your conference operator today.

Total Company Revenue increased 13.4% to $522.9 million in the third quarter of 2025 from $461.1 million in the third quarter of 2024; Revenue ...

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth.

Third quarter 2025 net loss was $ (16.3) million, or $ (0.26) per share, compared to $ (15.4) million, or $ (0.25) per share, for the same period in 2024. Adjusted EBITDA loss was $ (2.6) million in ...

Full-year 2025 guidance -- Revenue expected between $365 million-$375 million, non-GAAP gross margins of 78%-80%, non-GAAP ...

Sight Sciences ( (SGHT) ) just unveiled an announcement.

Eastern Bankshares, Inc. ("Eastern") (NASDAQ Global Select Market: EBC), the holding company for Eastern Bank, confirmed today that on November 1, 2025 Eastern completed its previously announced ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” third-quarter 2025 investor letter. A ...